



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 84250

Title: Rivaroxaban for the treatment of Heparin-induced Thrombocytopenia with Thrombosis in a patient undergoing artificial hip arthroplasty: A Case Report and Literature Review

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03001656

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Germany

Author's Country/Territory: China

Manuscript submission date: 2023-04-15

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-06-09 11:58

Reviewer performed review: 2023-06-15 07:57

Review time: 5 Days and 19 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty

Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation
Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Dear authors, I have some remarks: - the submission is very different concerning the quality of the english of the different sections of the text, the "submission" section is very good, the other parts need to be improved - the title deals with platelets, this point is not discussed in extenso in the subvmission, what is discussed and what is interesting is the treatment of HIT with Rivaroxaban. You should rethink your title or should focus more on the rivaroxaban. - the text is sometimes quite lengthyand should be shortened. General descriptions of HIT and PF4 are interesting but only cite other scientific work. - the incidence of HIT in LMWH patients is markedly lower than in UFH and is 0,1-0,5%. This should be changed in the text. Moreover it is not impossible that the UFH administration is source of the HIT. - please explain the ratio for warfarin therapy in a patient with pulmonary artery embolism. - the patient only had arterial thrombosis which is less common compared to venous thrombosis, were there specific risk factors?